ID Biologics

Date: 2020

Asset Class: Direct investment

Description:  ID Biologics discovers and develops human monoclonal antibodies for the prevention, treatment, and cure of infectious diseases. Their innovative fully human monoclonal antibody platform enables rapid discovery and optimization of broad and potent therapeutic molecules.

Why We Invest: Their focus on Covid-19 and flu antibodies are particularly relevant today.